FDA '522' Guidance: 15-Month Deadline To Comply With Postmarket Order
This article was originally published in The Gray Sheet
The agency has issued a final guidance on Sec. 522 postmarket study orders about five years after a draft version. In the interim, Congress stipulated a 15-month deadline for companies to start the FDA-mandated studies, a requirement emphasized in the new document.
Register for our free email digests: